Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 279-317-3 | CAS number: 79828-43-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 421
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- Test System
Species/strain: Wistar rats, Crl: WI(Han) (Full Barrier)
Source: Charles River, 97633 Sulzfeld, Germany
Sex: male and female; the female animals were non-pregnant and nulliparous.
Age at the start of the treatment period: approx. 10-11 weeks old
Body weight at the allocation of the animals to the experimental groups:
males: 264 - 314 g (mean: 295.53 g, ± 20% = 236.42 – 354.63 g)
females: 183 - 217 g (mean: 199.89 g, ± 20% = 159.91 – 239.86 g)
The animals were derived from a controlled full-barrier maintained breeding system (SPF). According to Art. 9.2, No. 7 of the German Act on Animal Welfare the animals were bred for experimental purposes.
Housing and Feeding Conditions
- Full barrier in an air-conditioned room
- Temperature: 22 +/- 3°C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. 0702)
- Free access to tap water, sulphur acidified to a pH of approximately 2.8 (drinking water, municipal residue control,
microbiological controls at regular intervals)
- The animals were kept individually in IVC cages (except during the mating period when one female will be paired with one male),
type III H, polysulphone cages on Altromin saw fibre bedding (lot no. 190612)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least 5 days) under laboratory conditions
Preparation of the Animals
Prior to the start of the treatment period a detailed clinical observation outside the home cage was made.
Before the first administration all animals used for the study were weighed and assigned to the experimental groups
with achieving a most homogenous variation in body weight throughout the groups of males and females.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- The test item was weighed into a tarred plastic vial on a suitable precision balance and the vehicle (sterile water) was added to give the appropriate final concentration of the test item.
The vehicle was selected as suggested by the sponsor and on the basis of the test item’s characteristics. The test item formulation was prepared freshly on each administration day before the administration procedure. The time of preparation was recorded for all dosing formulations.
Homogeneity of the test item in the vehicle was maintained by vortexing the prepared suspension thoroughly before every dose administration.
The vehicle was also used as control item.
The following doses were evaluated:
Control: 0 mg/kg body weight
Low Dose: 100 mg/kg body weight
Medium Dose: 300 mg/kg body weight
High Dose: 1000 mg/kg body weight
The highest dose level was chosen with the aim of inducing toxic effects, but no death or severe suffering.
Thereafter, a descending sequence of dose levels was selected with a view to demonstrate any dosage related response and NOAEL.
The animals in the control group were handled in an identical manner to the test group subjects and received the vehicle
using the same dose volume.
Dose volumes were adjusted individually based on weekly body weight measurements. The administration volume was 5 mL/kg body weight. - Details on analytical verification of doses or concentrations:
- Each dosing concentration were analysed with respect to the target nominal concentration. Stability and homogeneity of the test item in the
vehicle were analysed for the low and high dose concentrations.
Samples for the nominal concentration verification were taken in study week 1 (first week of pre-mating period), 3 (first week of mating), 5 (gestation) and 7 (gestation/lactation) from all groups (16 samples).
Samples for homogeneity analysis were taken from the top, middle and bottom of the high dose and the low dose formulation in study
week 1 and 5 (12 samples).
Samples for stability analysis were taken in the first week of the study, 0 hours after the preparation and another sample 6 hours after the preparation (at room temperature), from high and low dose formulations (4 samples).
All samples of dosing formulations were sent to Analytic department of BSL BIOSERVICE Scientific Laboratories GmbH on particular day of sampling.
Formulation analysis was performed in accordance with GLP and the procedures followed for the determination of test item concentration in the dosing formulations and control formulation were described in a separate study phase plan (BSL phase study No. 122442) issued by the Principal Investigator which was amended to study plan. - Details on mating procedure:
- Mating was performed using a ratio of 1:1 (male to female). The vaginal smear of the females was checked every morning after the start of the mating period to confirm the copulation. The day of the vaginal plug and/or sperm was considered as day 0 of gestation. The cages were arranged in such a way that possible effects due to cage placement were minimised. In case of unsuccessful mating, re-mating of females with proven males of the same group was considered.
- Duration of treatment / exposure:
- The female animals were treated with the test item formulation or vehicle on 7 days per week basis for approximately 54 days, i.e. during 14 days of pre-mating and 14 days of mating in both males and females, during the gestation period and up to post-natal day 3 in females. Males were dosed after the mating period until the minimum total dosing period of 28 days was completed.
- Frequency of treatment:
- 7 days/wk
- Duration of test:
- Study Initiation Date: 17 September 2012
1st Amendment to Study Plan: 14 December 2012
Experimental Starting Date: 26 September 2012
Experimental Completion Date: 18 November 2012
Completion Date of
Delegated Phase (Histopathology): 13 February 2013
Completion Date of
Delegated Phase
(Formulation Analysis): 18 February 2013
Date of Draft Report (BSL): 20 March 2013
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0; 100; 300; 1000 mg/kg body weight and day
Basis:
actual ingested
- No. of animals per sex per dose:
- 80 animals (40 males and 40 females) were included in the study (10 male and 10 female animals per group).
This included the control group animals shared with BSL study No. 122429. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Mating
Mating was performed using a ratio of 1:1 (male to female). The vaginal smear of the females was checked every morning after the start of the mating period to confirm the pregnancy. If the vaginal smear of a particular female was not found to be sperm-positive, the actual stage of the estrus cycle on that day was documented. The day of the vaginal plug and/or sperm was considered as day 0 of gestation. Females with unsuccessful mating will be allowed to mate with other male of the same group.
The cages were arranged in such a way that possible effects due to cage placement were minimised.
Body Weight and Food Consumption
The body weight was recorded once before the assignment to the experimental groups, on the first day of administration and weekly during the treatment period as well as at the end of the study.
During pregnancy, females were weighed on gestation days (GD) 0, 7, 14 and 20 and within 24 hours of parturition (day 0 post-partum) as well as day 4 post-partum along with pups. Any animals prematurely sacrificed were weighed prior to the sacrifice.
Food consumption was measured weekly on the corresponding days of the body weight measurements after the beginning of the dose administration. Food consumption was not measured during the mating period in males and females and the post-mating period in males.
Clinical Observations
General clinical observations were made at least once a day, preferably at the same time each day and considering the peak period of anticipated effects after dosing. The health condition of the animals was recorded. Twice daily all animals were observed for morbidity and mortality except on weekends and public holidays when observations were made once daily.
Females showing signs of abortion or premature delivery prior to the scheduled scarification of the animals were sacrificed and subjected to a thorough macroscopic examination.
Litter Observations
The duration of the gestation was recorded and was calculated from day 0 of the pregnancy. Each litter was examined as soon as possible after delivery of the dam to establish the number and sex of pups, stillbirths, live births, runts and the presence of gross abnormalities.
Live pups were counted and sexed and litters weighed within 24 hours of parturition (day 0 post-partum) and on day 4 post-partum. Live pups were identified by writing numbers on the back with the help of a permanent marker or by tattooing. In addition to the observations of parent animals, any abnormal behaviour of the offspring was recorded.
Examinations
- Fetal examinations:
- The duration of the gestation was recorded and was calculated from day 0 of the pregnancy. Each litter was examined as soon as possible after delivery of the dam to establish the number and sex of pups, stillbirths, live births, runts and the presence of gross abnormalities.
Live pups were counted and sexed and litters weighed within 24 hours of parturition (day 0 post-partum) and on day 4 post-partum. Live pups were identified by writing numbers on the back with the help of a permanent marker or by tattooing. In addition to the observations of parent animals, any abnormal behaviour of the offspring was recorded. - Statistics:
- A statistical assessment of the results of the body weight, food consumption, parameters of absolute and relative organ weights were performed for each gender by comparing values of dosed with control animals of the main groups using a one-way ANOVA and a post-hoc Dunnett Test. These statistics were performed with GraphPad Prism 5.01 software (p<0.05 was considered as statistically significant).
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Details on maternal toxic effects:
Mortality
No mortalities were observed at any dose levels of male and female animals.
Clinical Observations
No test item related clinical signs were observed in male and female animals during the entire study period. However, few specific findings observed in few male and female animals of treatment groups were slight to severe piloerection, bradykinesia, abnormal breathing, moving the bedding, alopecia on various body parts and salivation. As these clinical signs were observed on few days of the treatment period, in very few animals and in absence of any effect on parameters of general health like body weight and food consumption in treatment groups, these findings were considered to be non adverse.
Body Weight Development
In male and females, no statistically significant effect on body weight and body weight gain was observed throughout the study period in treatment groups except significant increase during premating day 7-14 in HD males and significant decrease during gestation day 0-7 in LD and MD group females was observed when compared with controls. Since it was increase in body weight gain in males and due to lack of dose dependency in decrease in body weight gain during gestation day 0-7 in females, this significant effect was considered to be toxicologically irrelevant.
Food Consumption
In males, statistical analysis of food consumption data revealed no statistically significant effect in treatment groups when compared with controls.
In females, statistical analysis of food consumption data revealed significant decrease during gestation day 0-7 and 7-14 in LD and MD group females when compared with controls. As no test item related effect on group mean body weight was observed during that period and due to lack of dose dependency in decrease in food consumption, this significant effect on food consumption was considered to be non adverse.
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Details on embryotoxic / teratogenic effects:
Litter Data
No treatment related effect was observed on total number of pups born, number of males, number of females, sex ratio, live pups, still birth and runt on PND 0 and number of males, number of females, total number of pups and sex ratio on PND 4.
All group mean and individual values for various litter data parameters from treatment groups were comparable with the controls.
Litter Weight Data
Statistical analysis of litter weight data revealed no treatment related effect on group mean litter weight, total litter weight, male litter weight and female litter weight on PND 0 and PND 4 when compared with corresponding controls.
Precoital Interval and Duration of Gestation
No treatment related effect was observed on precoital interval and duration of gestation and values were comparable between the groups. All pregnancies resulted in normal births.
All females in control and treatment groups showed evidence of copulation during 14 days mating period except one female from MD group (No. 127) did not show evidence of mating through vaginal smear. However, animal was pregnant and littered normally.
Successful mating resulted in 9, 9, 10 and 7 pregnancies in the control, low, mid and high dose respectively.
Pre- and Post-Natal Data
Pre and post natal data like group mean number of corpora lutea, number of implantation sites, number of pups born on PND 0, percent preimplantation and post implantation loss remained unaffected due to treatment when compared with controls.
Reproductive Indices
No treatment related effect on copulation index, delivery index and viability index was observed when compared with controls.
Reduced fertility index (No. of pregnant females/No. of copulated females X 100) was observed in HD (70 %) dose group as compared to C (90%), LD (90%) and MD groups (100 %).
Pup Survival Data
No significant effect on survival of the pups from PND 0 to PND 4 was observed in any treatment group when compared with controls.
Survival of the pups from PND 0 to PND 4 remained unaffected due to the treatment in all treatment groups and no pup mortality was observed in this study except one pup from HD group female 133 (pup No. 4) was found dead on PND 2. Since this pup mortalitiy was observed in one female and just one pup was dead, this incidence was not considered to be test item related.
Pup External Findings
No treatment related gross external findings were observed in pups from any of the treated groups on PND 0 and 4. However, following few external findings were observed:
In control females, one pup from female 45 (pup No. 3) was observed for hematoma at head on PND 0.
In LD females, one pup from female 116 (pup No. 2) was observed for redness on the nose on PND 0.
In HD females, one pup from female 140 (pup No. 2) was observed for dark spot at the neck on PND 0.
All these findings were considered to be spontaneous in nature and not related to the treatment with test item.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- no
Any other information on results incl. tables
Pathology
At necropsy of male (after minimum total dosing of 28 days - on day 29) and females (on post-natal day 4) by using a high dose of Ketamine/Xylazine (3:1), macroscopic examination of the animals revealed no test item related macroscopic findings in males and females. Few spontaneous gross pathological findings observed in MD and HD male animals were yellow spots on epididymides, dark discolouration of organs like kidneys and mesenteric lymph nodes. These findings related to discolouration in males were attributed to the colour of the test item and as such not a systemic effect due to the test item administration.
Organ Weight
In males, statistical analysis of organ weight data revealed, statistically significant decrease in absolute prostate (with seminal vesicles and coagulating gland) weight in MD group and relative prostate weight in HD group when compared with the control. Since the difference in group mean absolute and relative prostate weight was marginal and in the light of absence of histopathological findings, this significant effect on prostate weight was considered to be non adverse.
In females, no statistically significant effect on absolute and relative (to body weight) organ weights was observed in any treatment group when compared with the controls.
Histopathology
Dark discoloration of kidney and/or mesenteric lymph node was observed in all males treated at 1000 mg/kg/day and a proportion of males treated at 300 mg/kg/day. At 100 mg/kg/day, mesenteric lymph node of one single male was discolored dark. These color changes were considered to be caused by the color of the test item itself, but were not evaluated histologically according to the study plan.
Histologically, no test item-related findings were noted in the male and female reproductive organs. Reproductive organs of most females showed typical post-partum histomorphology. One control female, one female treated at 100 mg/kg/day and three females treated at 1000 mg/kg/day did not show any indication of recent pregnancy at terminal sacrifice. This was considered to be unrelated to treatment, as histomorphology of their reproductive organs indicated physiological sexual cycling.
As a conclusion, no test item-related pathological lesions were noted in male and female reproductive organs in this study. The NOAEL (No Observed Adverse Effect Level) for pathology of reproductive organs is therefore considered to be 1000 mg/kg/day under the conditions of this study.
Macroscopic colour changes of kidney and mesenteric lymph node were considered to be directly caused by the test item, but were not evaluated histologically.
Dose Formulation Analysis
Concentration analysis of formulation samples was determined in study week 1, 3, 5 and 7 for all dose groups. The mean recoveries observed in LD, MD and HD groups were 109.2%, 107.5% and 90.5% of the nominal concentration, respectively.
Stability of formulation samples was investigated in study week 1 for LD and HD dose groups. After 6 hours storage at -20°C recovery compared to starting value was 112.3 and 98.9%.
Homogeneity of formulation samples was determined in study week 1 and 5 for LD and HD dose groups. The mean recovery observed for LD dose group was 113.9 and 105.8% of the nominal value, and 89.5 and 106.5% for HD dose group. The coefficients of variation of the different sampling locations (top, middle and bottom) were 3.2 and 1.7% in LD dose group, and 2.5 and 2.2% in HD dose group.
Applicant's summary and conclusion
- Conclusions:
- Based on the data generated from this reproduction/ developmental toxicity screening test with FAT 40821/A, the no observed adverse effect level (NOAEL) is considered to be 1000 mg/kg body weight for reproduction/ developmental toxicity screening in males and females.
- Executive summary:
This study was performed with the aim to assess the possible effects of FAT 40821/A on male and female fertility and embryofetal development after repeated dose administration in Wistar rats.
The test item was administered daily in graduated doses to 3 groups of test animals, one dose level per group for a treatment period of 54 days, i.e. during 14 days of pre-mating and 14 days of mating in both males and females, during the gestation period and up to post-natal day 3 in females. Males were dosed after the mating period until the minimum total dosing period of 28 days were completed. Animals of an additional control group were handled identically as the dose groups but receivedaqua ad injectionem(sterile water), the vehicle used in this study. The 4 groups comprised 10 male and 10 female Wistar rats.
During the period of administration, the animals were observed each day for signs of toxicity. Animals that died were examined macroscopically and at the conclusion of the test, surviving animals were sacrificed and observed macroscopically.
Body weight and food consumption were measured weekly, except for food consumption measurements which were not taken during the mating period in female animals and the mating and post-mating period in male animals.
After 14 days of treatment to both male and female, animals were mated (1:1) for a maximum of 14 days. The subsequent morning onwards the vaginal smears of females were checked to confirm the evidence of mating. After the confirmation of the mating, females were separated and housed individually. Each litter was examined as soon as possible after delivery of the dam to establish the number and sex of pups, stillbirths, live births, runts and the presence of gross abnormalities. Live pups were counted, sexed and litters weighed within 24 hours of parturition and on day 4 post-partum.
The males were sacrificed after completion of the mating period on treatment day 30 and the females along with their pups were sacrificed on post natal day 4. Non-pregnant females were sacrificed on day 26. The number of implantation sites and corpora lutea was recorded for each parental female at necropsy.
Pups sacrificed on postnatal day 4 and those found dead, were carefully examined for gross external abnormalities.
A full histopathological evaluation of testes, epididymides, ovaries, uterus with cervix, vagina, accessory sex organs (prostate, seminal vesicle with coagulating gland) from C and HD Group animals and all organs showing gross lesions except discolorations due to the color of the test item were examined.
Female reproductive organs were also evaluated in non-pregnant females.
The following doses were evaluated:
Control: 0 mg/kg body weight;Low Dose: 100mg/kg body weight;Medium Dose: 300 mg/kg body weight, High Dose: 1000 mg/kg body weight
The test item formulation was prepared freshly on each day of administration. The test item was dissolved inaqua ad injectionem(sterile water) and administered daily during 14 days of pre-mating and 14 days of mating in both male and female animals, during the gestation period and up to post-natal day 3 in females. Males were dosed for 28 days. Dose volumes were adjusted individually based on weekly body weight measurements. Theadministration volume was 5 mL/kg body weight.
Summary Results
Mortality
No mortality occurred in the control or any of the dose groups during the treatment period of this study.
Clinical Signs
No test item related clinical signs were observed in male and female animals during the entire study period. However, few specific findings observed in few male and female animals of treatment groups were slight to severe piloerection, bradykinesia, abnormal breathing, moving the bedding, alopecia on various body parts and salivation.
Body Weight Development
In male and females, no statistically significant effect on body weight and body weight gain was observed throughout the study period in treatment groups except significant increase during premating day 7-14 in HD males and significant decrease during gestation day 0-7 in LD and MD group females was observed when compared with controls.
Food Consumption
In males, statistical analysis of food consumption data revealed no statistically significant effect in treatment groups when compared with controls.
In females, statistical analysis of food consumption data revealed significant decrease during gestation day 0-7 and 7-14 in LD and MD group females when
compared with controls.
Litter Data
No treatment related effect was observed on total number of pups born, number of males, number of females, sex ratio, live pups, still birth and runt on PND 0
and number of males, number of females, total number of pups and sex ratio on PND 4.
Litter Weight Data
Statistical analysis of litter weight data revealed no treatment related effect on group mean litter weight, total litter weight, male litter weight and female litter weight on PND 0 and PND 4 when compared with corresponding controls.
Precoital Interval and duration of Gestation
No treatment related effect was observed on precoital interval and duration of gestation and valueswere comparable between the groups. All pregnancies resulted in normal births.
Pre and Post Natal Data
Pre and post natal data like group mean number of corpora lutea, number of implantation sites, number of pups born on PND 0, percent preimplantation and post implantation loss remained unaffected due to treatment when compared with controls.
Reproductive Indices
No treatment related effect on copulation index, delivery index and viability index was observed when compared with controls.
Reduced fertility index (No. of pregnant females/No. of copulated females X 100) was observed in HD (70 %) dose group as compared to C (90%), LD (90%)
and MD groups (100 %).
Pup Survival Data
No significant effect on survival of the pups from PND 0 to PND 4 was observed in any treatment group when compared with controls.
Survival of the pups from PND 0 to PND 4 remained unaffected due to the treatment in all treatment groups and no pup mortality was observed in this study
except one pup from HD group female 133 (pup No. 4) was found dead on PND 2.
Pup external Findings
No treatment related gross external findings were observed in pups from any of the treated groups on PND 0 and 4. However, few spontaneous findings like
hematoma at head in one pup from control group female, redness on the nose in one pup from LD group female and dark spot at the neck in one pup from HD
group was observed on PND 0.
All these findings were considered to be spontaneous in nature and not related to the treatment with test item.
Pathology
At necropsy of male and females, macroscopic examination of the animals revealed no test item related macroscopic findings in males and females.
Fewspontaneous gross pathological findings observed in MD and HD male animals wereyellow spotson epididymides, dark discolouration of organs like kidneysand mesenteric lymph nodes.
Organ Weight
In males, statistical analysis of organ weight data revealed, statistically significant decrease in absolute prostate (with seminal vesicles and coagulating gland)weight in MD group and relative prostate weight in HD group when compared with the control.
In females, no statistically significant effect on absolute and relative (to body weight) organ weights was observed in any treatment group when compared with the controls.
Histopathology
Histologically, no test item-related findings were noted in the male and female reproductive organs. Reproductive organs of most females showed typical post-partum histomorphology. One control female, one female treated at 100 mg/kg/day and three females treated at 1000 mg/kg/day did not show any indication of recent pregnancy at terminal sacrifice. This was considered to be unrelated to treatment, as histomorphology of their reproductive organs indicated physiological sexual cycling.
As a conclusion, no test item-related pathological lesions were noted in male and female reproductive organs in this study. The NOAEL (No Observed Adverse Effect Level) for pathology of reproductive organs is therefore considered to be 1000 mg/kg/day under the conditions of this study.
Macroscopic colour changes of kidney and mesenteric lymph node were considered to be directly caused by the test item, but were not evaluated histologically.
Dose Formulation Analysis
Concentration analysis of formulation samples was determined in study week 1, 3, 5 and 7 for all dose groups. The mean recoveries observed in LD, MD and HD groups were 109.2%, 107.5% and 90.5% of the nominal concentration, respectively.
Stability of formulation samples was investigated in study week 1 for LD and HD dose groups. After 6 hours storage at -20°C recovery compared to starting value
was 112.3 and 98.9%.
Homogeneity of formulation samples was determined in study week 1 and 5 for LD and HD dose groups. The mean recovery observed for LD dose group
was 113.9 and 105.8% of the nominal value, and 89.5 and 106.5% for HD dose group. The coefficients of variation of the different sampling locations
(top, middle, bottom) were 3.2 and 1.7% in LD dose group, and 2.5 and 2.2% in HD dose group.
Conclusion
In conclusion, the repeated dose administration of FAT 40821/A in sterile water to the male (28 days) and female (maximum 54 days) Wistar rats at dosages of 100, 300 and 1000 mg/kg body weight revealed neither mortalities nor findings of toxicological relevance.
Based on the data generated from this reproduction/ developmental toxicity screening test withFAT 40821/A, the no observed adverse effect level (NOAEL) is considered to be 1000 mg/kg body weight forreproduction/ developmental toxicity screening in males and females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies